Search for: "TTS, LLC"
Results 1 - 20
of 59
Sorted by Relevance
|
Sort by Date
28 Mar 2024, 9:15 am
Harris Brumfield, as Trustee for Ascent Trust, is the successor to TT, which sued IBG LLC in 2010 for infringement of four patents: U.S. [read post]
28 Mar 2024, 9:15 am
Harris Brumfield, as Trustee for Ascent Trust, is the successor to TT, which sued IBG LLC in 2010 for infringement of four patents: U.S. [read post]
3 Apr 2007, 4:23 am
Rosenthal Collins Group, LLC v. [read post]
22 Jun 2007, 4:07 am
Rosenthal Collins Group, LLC v. [read post]
22 Jun 2007, 4:07 am
Rosenthal Collins Group, LLC v. [read post]
11 Jan 2021, 3:28 pm
IBG LLC, Case No. 10 C 715 (N.D. [read post]
24 Jul 2008, 11:10 am
Rosenthal Collins Group, LLC v. [read post]
2 Mar 2011, 2:28 am
Rosenthal Collins Group, LLC v. [read post]
7 Apr 2013, 9:37 pm
.; Noven Therapeutics LLC; Hisamitsu Pharmaceutical Co. [read post]
3 Feb 2014, 9:51 pm
.; Noven Therapeutics LLC; Hisamitsu Pharmaceutical Co. [read post]
16 Apr 2019, 5:00 pm
At the time of the alleged fraud, Class TT was managed by Albert Hallac (“Hallac”), Jeffrey Hallac (“Jeffrey”), and Keith Wellner, through Weston Capital Asset Management, LLC and its related affiliate Weston Capital Management LLC. [read post]
16 Apr 2019, 5:00 pm
At the time of the alleged fraud, Class TT was managed by Albert Hallac (“Hallac”), Jeffrey Hallac (“Jeffrey”), and Keith Wellner, through Weston Capital Asset Management, LLC and its related affiliate Weston Capital Management LLC. [read post]
20 Aug 2008, 10:41 am
Rosenthal Collins Group, LLC v. [read post]
24 Apr 2019, 5:15 am
" In previous Federal Circuit cases, Trading Technologies (TT) patents had been determined not eligible for CBM review as they were technological inventions or were found patent eligible. [read post]
7 Sep 2010, 3:40 am
Rosenthal Collins Group, LLC v. [read post]
13 Feb 2014, 8:36 am
We also examined the RR for PDE5I and compared the RRs in the TT prescription and PDE5I cohorts.Also:Among men aged 65 years and older, we observed a two-fold increase in the risk of MI in the 90 days after filling an initial TT prescription, the risk declined to baseline in the 91 to 180 days after initial TT prescription, among those who did not refill their prescription. [read post]
29 Jul 2008, 11:16 am
Rosenthal Collins Group, LLC v. [read post]
16 Oct 2009, 3:29 am
Rosenthal Collins Group, LLC v. [read post]
1 Mar 2011, 2:00 am
Rosenthal Collins Group, LLC v. [read post]
19 Oct 2011, 4:08 am
Rosenthal Collins Group, LLC v. [read post]
